No association between the tacrine transaminitis and the glutathione transferase θ genotype in patients with Alzheimer's disease

Pharmacogenetics

Volumn 8, Issue 4, 1998, Pages 353-355

  De Sousa, Michelle ^a   Pirmohamed, Munir ^a   Kitteringham, Neil R ^a   Woolf, Thomas ^b   Park, Brian Kevin ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b PFIZER INC   (United States)

Author keywords

GSTT1*0; Hepatotoxicity; Tacrine

Indexed keywords

ALANINE AMINOTRANSFERASE; TACRINE;

ALZHEIMER DISEASE; CLINICAL TRIAL; CONTROLLED STUDY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN TISSUE; LIVER TOXICITY; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SHORT SURVEY;

ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; DNA PRIMERS; GENE FREQUENCY; GENOTYPE; GLUTATHIONE TRANSFERASE; HUMANS; LIVER DISEASES; TACRINE; TRANSAMINASES;

EID: 0031826404     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (16)

1. Arand M, Mühlbauer J, Hengstler J, Jäger S, Fuchs J, Winkler L, et al. A multiplex polymerase chain reaction protocol for the simultaneous analysis of the glutathione S-transferase GSTM1 and GSTT1 polymorphisms. Anal Biochem 1996; 236:184-186.
2. Becquemont L, Lecoeur S, Simon T, Beaune P, Funck-Brentano C, Jaillon P, Glutathione S-transferase θ genetic polymorphism might influence tacrine hepatotoxicity in Alzheimer's patients. Pharmacogenetics 1997; 7:251-253.
3. Brockmöller J, Gross D, Kerb R, Drakoulis N, Roots I. Correlation between trans-stilbene oxide-glutathione conjugation activity and the deletion mutation in the glutathione S-transferase class Mu gene detected by polymerase chain reaction. Biochem Pharmacol 1992; 43:647-650.
4. Chen H, Sandler DP, Taylor JA, Shore DL, Liu E, Bloomfield CD, et al. Increased risk for myelodysplastic syndromes in individuals with glutathione transferase theta 1 (GSTT1) gene defect. Lancet 1996; 347:295-297.
5. Elexpuru-Camiruaga J, Buxton N, Kandula V, Dias PS, Campbell D, McIntosh J, et al. Susceptibility to astrocytoma and meningioma: influence of allelism at glutathione S-transferase (GSTT1 and GSTM1) and cytochrome P-450 (CYP2D6) loci. Cancer Res 1995; 55:4237-4239.
6. Green VJ, Pirmohamed M, Kitteringham NR, Knapp MJ, Park BK. Glutathione S-transferase μ genotype (GSTM1*0) in Alzheimer's patients with tacrine transaminitis. Br J Clin Pharmacol 1995; 39:411-115.
7. Hayes JD, Pulford DJ. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 1995; 30:445-600.
8. Irving J, Feng JL, Wistrom C, Pikaart M, Villeponteau B. An altered repertoire of fos (AP-1) at the onset of replicative senescence. Exp Cell Res 1992; 202:161-166.
9. Katoh T, Nagata N, Kuroda Y, Itoh H, Kawahara A, Kuroki N, et al. Glutathione S-transferase M1 (GSTM1) and T1 (GSTT1) genetic polymorphism and susceptibility to gastric and colorectal adenocarcinoma. Carcinogenesis 1996; 17:1855-1859.
10. Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI. A 30-week randomised controlled trial of high-dose tacrine in patients with Alzheimer's disease. J Am Med Ass 1994; 271:985-991.
11. Madden S, Woolf TF, Pool WF, Park BK. An investigation into the formation of stable, protein-reactive and cytotoxic metabolites from tacrine in vitro: studies with human and rat liver microsomes. Biochem Pharmac 1993; 46:13-20.
12. Nelson HH, Wiencke JK, Christiani DC, Cheng TJ, Zuo ZF, Schwartz BS, et al. Ethnic differences in the prevalence of the homozygous deleted genotype of glutathione S-transferase theta. Carcinogenesis 1995; 16:1243-1245.
13. Pemble S, Schroeder KR, Spencer SR, Meyer DJ, Hallier E, Bolt HM, et al. Human glutathione S-transferase theta (GSTT1): cDNA cloning and the characterisation of a genetic polymorphism. Biochem J 1994; 300:271-276.
14. Warholm M, Rane A, Alexandrie A-K, Monaghan G, Rannung A. Genotypic and phenotypic determination of polymorphic glutathione transferase T1 in a Swedish population. Pharmacogenetics 1995; 5:252-254.
15. Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 1994; 271:992-998.
16. Woolf TF, Bjorge SM, Chang T, Goel OP, Purchase CF, Schroeder MC, et al. Bioactivation and irreversible binding of the cognition activator tacrine using human and rat liver microsomal preparation. Drug Metab Dispos 1993; 21:874-882.